At a Glance
Acromegaly is a rare chronic endocrine disorder caused by the hypersecretion of growth hormone (GH) from the anterior pituitary gland in adults. A GH-secreting adenoma of the pituitary gland is the most common cause of acromegaly. Rarely, GH may be secreted by some malignancies.
Acromegaly is indolent with symptoms often preceding diagnosis by several years. Visual field defects and persistent headaches are common complaints caused by expansion of the adenoma. The tumor may also compromise normal pituitary tissue leading to deficiencies of other pituitary hormones.
Because GH stimulates the hepatic synthesis of insulin-like growth factor 1 (IGF-1), other symptoms of acromegaly are related to the excess GH and IGF-1 secretion and include:
Enlargement of the extremities
Increase in ring and/or shoe size
Coarsening of facial features
Prognathism (growth of mandible)
Acromegalics have an increased risk of developing diabetes mellitus, hypertension, cardiovascular disease, and congestive heart failure. They also show a greater incidence of premalignant colon polyps that increases the risk of colon cancer.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
GH and IGF-1 testing is indicated for individuals with headaches and musculoskeletal growth. Because GH secretion is pulsatile, its concentration in acromegaly may be within the established reference interval. In contrast, serum concentrations of IGF-1 are relatively constant and are usually elevated in acromegaly. Thus, IGF-1 is the best single test for diagnosis. Acromegaly is excluded, if the GH concentration is less than 0.3 ng/mL in conjunction with a concentration of IGF-1 within the established reference interval.
GH secretion is inhibited by glucose. Individuals with active acromegaly are unable to suppress GH concentration after an oral glucose tolerance test. After administering 75 grams of glucose, samples are obtained over 120 minutes. Failure to suppress GH (<0.3 ng/mL) at 120 minutes is diagnostic of acromegaly. If GH is suppressed, then acromegaly is excluded.
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
Age- and gender-specific reference intervals are required for accurate interpretation of IGF-1. Starvation, obesity, and diabetes mellitus decrease and pregnancy increases concentrations of IGF-1.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Plastics and Cancer
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship